All In Biotech

Free tool

FAERS Monitor: Nuzyra

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209816 or its brand name (Nuzyra, Omadacycline Tosylate). Reports on generic versions are filed under their own applications.

Reports

1,716

Serious

997

58% of reports

Hospitalization

422

Death reported

118

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use454
  • nausea268
  • vomiting166
  • drug ineffective128
  • diarrhoea125
  • incorrect product administration duration95
  • dyspnoea88
  • rash86
  • fatigue73
  • death72
  • incorrect dose administered69
  • hospitalisation62
  • pruritus59
  • aspartate aminotransferase increased57
  • headache55

Reports by year received

View as table
YearReports
20171
201935
2020109
2021145
2022152
2023296
2024348
2025399
2026231

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,443 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
incorrect product administration durationSignal9554.044.44,871
aspartate aminotransferase increasedSignal5713.210.2630
off label useSignal4546.45.92,132
hospitalisationSignal624.93.9193
vomitingSignal1664.33.7431
nauseaSignal2684.23.7663
incorrect dose administeredSignal693.72.9135
rashSignal862.42.072
diarrhoeaSignal1252.42.0101
dyspnoea881.91.638
pruritus591.91.524
drug ineffective1281.21.04
fatigue731.10.91
headache551.10.80
death721.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.